(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
How AI fixed the James Webb Space Telescope's blurry vision- Find the Lively Food Markets of South America
- A Manual for Extravagant Vehicles Available in 2024
- Amazon sued over 'punitive' handling of employee absences
- Auschwitz Committee wants German auction of Holocaust items scrapped
- Presenting Nintendo's New Pastel Euphoria Con Tones for Switch Gamers: 3 Trendy Choices
- Best Internet based Course for Learning Another Dialect: Which Stage Do You Like?
- Scientists solve the mystery of the prehistoric 'Burtele Foot'
- My Enterprising Excursion: Building a Startup
